Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2025 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors.Combining CTX-471 with tovecimig (CTX-009) markedly increased...
October 23, 2024 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...
September 03, 2024 14:02 ET | Source: 7 Hills Pharma

7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.
June 05, 2024 22:00 ET | Source: Bragar Eagel & Squire

CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Checkpoint Therapeutics,...
June 04, 2024 10:20 ET | Source: Schall Law

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
June 03, 2024 12:57 ET | Source: 7 Hills Pharma

7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic

Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
May 31, 2024 21:00 ET | Source: Bragar Eagel & Squire

CHECKPOINT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Checkpoint Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against...
May 28, 2024 10:40 ET | Source: Schall Law

7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
May 21, 2024 11:00 ET | Source: Schall Law

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
May 16, 2024 22:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Checkpoint, Ocugen, and Sonder Innovations and Encourages Investors to Contact the Firm

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...

Next Page keyboard_arrow_right